ANZCTR search results

The purpose of this study is to test the safety of a new treatment (Dz13 combined with DOPE and DOTAP) for nodular BCC, a form of skin cancer. Dz13 is a small piece of DNA which binds to an mRNA molecule in the cell which in turn produces a specific protein known as c-Jun. The c-Jun gene is known to be abnormally active in many types of cancer cells, including BCC, causing the abnormal production of the c-Jun protein molecule. The c-Jun protein is involved in 'switiching on' other genes involved in cell growth, resulting in growth and spread of tumour cells. Dz13 binds to the c-Jun mRNA and chops it into two pieces, which disrupts production of the c-Jun protein and limits the growth and spread of the tumour. c-Jun is present at very low levels in normal adult tissues and is mostly expressed at high levels in tumour tissue. It is hypothesised that Dz13 will be able to stop the growth and spread of BCC and other skin tumours without significant toxicity. Dz13 has been shown in animal studies to be well tolerated at doses 35-fold higher than the highest dose that will be used in this study.

The study objective is to investigate the metabolic effects of beta2-agonist in humans, including whole body energy expenditure, fat oxidation, protein synthesis and turnover

The purpose of this study is to investigate whether the benefits of chemotherapy can be improved in women with relapsed ovarian cancer, by adding a new drug called Cediranib. Chemotherapy describes drug treatments which kill or control the growth of cancer cells. Cediranib is a ‘targeted therapy’ rather than a chemotherapy drug. As cancers grow they need to develop their own new blood supply to survive and this development of new blood supply vessels is known as angiogenesis. Cediranib works by slowing or stopping the growth of these new blood vessels which will hopefully interfere with the tumour’s ability to grow and spread to other parts of the body. It may also make the planned chemotherapy more effective. We believe that this may be an important new way to treat cancer. Although there are good scientific reasons from laboratory studies why Cediranib should work on ovarian cancer cells, it has not yet been tested in a large number of women with ovarian cancer. Cediranib is an investigational medical product which is not licensed for use in treatment of ovarian cancer or any other cancer

The purpose of this clinical study is to evaluate the effectiveness of the procedure for contrast removal as well as describe the safety and device performance of the Osprey Medical CINCOR Contrast Removal System, in patients with chronic kidney disease who are schedule to undergo diagnostic or therapeutic percutaneous coronary interventional procedures.

The study wishes to explore whether using metformin from early in the second trimester of pregnancy can reduce the risk of recurrence of gestational diabetes. The primary hypothesis is that "oral metformin, administered from early in the second trimester to women with a past history of gestational diabetes, will reduce the risk of recurrent gestational diabetes". Pregnant women who have had gestational diabetes in a previous pregnancy will be invited to participate. They must be between 12 and 16 weeks gestation at the time of study enrolment. Once a woman has given her informed consent she will undergo an oral Glucose Tolerance Test (oGTT) and a fasting blood sample will be stored for measurement of insulin and other hormones. Any women with a positive oGTT will not be eligible for the study and will be given appropriate counselling and treatment for her recurrent gestational diabetes (rGDM). Those who have a normal oGTT result will be eligible to have medication randomly allocated. Baseline demographic and clinical data will be collected. Women will be randomised to medication. Neither the woman nor the study team will know whether the woman is receiving active treatment or placebo. The woman will take her medication at the rate of one tablet per night for the next week. The dose will be increased by one tablet per week until a dose of four tablets a day is reached, or fewer as tolerated. Standard antenatal care will be received by all women on the study. At 26-28 weeks gestation participants will be weighed, measured and have repeat oGTT and blood sample as above. Any women found to have rGDM will continue with her study medication and receive appropriate counselling and treatment of the rGDM. At 35-36 weeks gestation the participants will again have a fasting blood sample taken, be weighed and measured. Birth of the baby will be planned in conjunction with obstetric team, depending on obstetric and medical factors present at the time. Study medication may be stopped at onset of labour or 12hours prior to a booked caesarean section. A sample of the cord blood will be collected for measurement of glucose, insulin and other hormones. The baby will receive standard care as for the baby of a diabetic mother. The baby will have standard measures done, along with some extra ones for the study. At 6 weeks after birth, the mother and baby will be measured again. The mother will undergo a repeat oGTT, as is standard for women with GDM, to determine if there is any ongoing diabetes or glucose intolerance. At this time a blood sample will again be taken for measurement of insulin and other hormones.

The primary purpose of this study is the examine the cerebral injury and changes in cerebral structure in late preterm and term infants undergoing surgery using neurobehvavioural, electrophysiology and MR imaging. Our study hypothesis is that childhood survivors of infants undergoing surgery in the newborn period for conditions including oesophageal atresia, congenital diaphragmatic hernia and gastroschisis will have impaired neurodevelopment.

Skeletal anterior open bite malocclusion is one of the most difficult malocclusions to treat orthodontically. Traditional treatment was aimed at correcting the malocclusion through a combination of orthodontics and orthognathic surgery, once growth was completed. Although good results were achieved, the treatment was complicated and severe invasive. With the advent of skeletal anchorage and miniscrews it has now become possible to treat Skeletal anterior open bite malocclusions non-surgically through intrusion of the maxillary posterior teeth, resulting in the closure of the anterior open bite. However, the appliances currently used for the intrusion are crude adaptions of existing auxillaries, not meant for this purpose. The have significant short comings including tissue irritaion, trauma and the need for frequent reactivation. The Sydney Intrusion Spring (SIS) is an appliance that has been specifically designed for the intrusion of maxillary posterior teeth. The aim of the study is to analyse the efficacy of this appliance on the intrusion of maxillary posterior teeth.

We intend to demonstrate whether the new Sonoplex needle is easier to see under ultrasound scanning than our standard Nanopline needle during routine anaesthetic nerve block procedures. This has already been shown in laboratory studies but not in live patients. We routimely use ultrasound to guide the passage of the nerve block needle and observe the spread of local anaesthetic around the nerve when performing nerve blocks for pain relief. We intend to recruit patients who are having nerve blocks as part of their routine anaesthetic and to randomise them (like flipping a coin) to having each block performed with either the Sonoplex or the Nanoline needle. We will record the ultrasound pictures anonomously for analysis. We will ask the anaesthetist performing the block to score how well they could see the needle tip and we will also assess this on the video data.

The purpose of this study is to determine which of two different intravenous anticoagulant strategies, currently in clinical use, is the safest and will have less associated bleeding complications. The study aims to test the hypothesis that use of bivalirudin has a lower rate of bleeding complications compared to heparin and glycoprotein IIb/IIIa inhibitor use.

The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.